Gamida Cell Ltd. (NASDAQ:GMDA) will hold its 2Q20 earnings conference call with the financial community on 11th August 2020 at 8:30 AM Eastern Time.
The conference call will be webcast live on Internet at www.gamida-cell.com
Earnings Expectation
Gamida Cell Ltd. is set to announce second quarter earning results on Tuesday 11th August 2020, before market open.
Analysts surveyed by Thomson Reuters are predicting, GMDA to report 2Q20 loss of $ 0.3 per share from revenue of $ 0.14 million. For the full year, analysts anticipate top line of $ 0.39 million, while looking forward to loss of $ 1.29 per share bottom line.
Gamida Cell Ltd., a clinical stage biopharmaceutical company, focuses on developing cell therapies to cure cancer, and rare and serious hematologic diseases. The companys lead product candidate is NiCord, a nicotinamide (NAM)-expanded cord blood cell therapy that is in Phase III studies in patients with high-risk hematologic malignancies, as well as in Phase I/II studies in patients with severe aplastic anemia. It is also developing NAM-NK, an innate immunotherapy, which is in Phase I studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma.
